115 related articles for article (PubMed ID: 8396823)
1. Cell surface receptors and bispecific monoclonal antibodies: the link between basic science and medical oncology.
Malavasi F; De Monte LB; Funaro A; Magrini E; Bonino LD; Momo M; Mariani M; Horenstein A; Natali PG
Year Immunol; 1993; 7():74-80. PubMed ID: 8396823
[No Abstract] [Full Text] [Related]
2. Tumor reactive T cells get a boost.
Pardoll DM
Nat Biotechnol; 2002 Dec; 20(12):1207-8. PubMed ID: 12454671
[No Abstract] [Full Text] [Related]
3. A revival of bispecific antibodies.
Kufer P; Lutterbüse R; Baeuerle PA
Trends Biotechnol; 2004 May; 22(5):238-44. PubMed ID: 15109810
[No Abstract] [Full Text] [Related]
4. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
5. Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein.
Krauss J; Arndt MA; Vu BK; Newton DL; Seeber S; Rybak SM
Biochem Biophys Res Commun; 2005 Jun; 331(2):595-602. PubMed ID: 15850802
[TBL] [Abstract][Full Text] [Related]
6. Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity.
Liao KW; Chen BM; Liu TB; Tzou SC; Lin YM; Lin KF; Su CI; Roffler SR
Cancer Gene Ther; 2003 Oct; 10(10):779-90. PubMed ID: 14502231
[TBL] [Abstract][Full Text] [Related]
7. Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy.
Reisfeld RA; Gillies SD
J Clin Lab Anal; 1996; 10(3):160-6. PubMed ID: 8731505
[No Abstract] [Full Text] [Related]
8. Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway.
Dincq S; Bosman F; Buyse MA; Degrieck R; Celis L; de Boer M; Van Doorsselaere V; Sablon E
Protein Expr Purif; 2001 Jun; 22(1):11-24. PubMed ID: 11388794
[TBL] [Abstract][Full Text] [Related]
9. Future directions in tumor immunotherapy: CTLA4 blockade.
Gulley JL; Dahut WL
Nat Clin Pract Oncol; 2007 Mar; 4(3):136-7. PubMed ID: 17327854
[No Abstract] [Full Text] [Related]
10. Lymphocyte ontogeny and membrane markers.
Goust JM; Jackson A
Immunol Ser; 1993; 58():161-86. PubMed ID: 8424972
[No Abstract] [Full Text] [Related]
11. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
12. [Antibody and immunotherapy in oncology. Which patients benefit?].
Schlimok G
MMW Fortschr Med; 2001 Jun; 143(25):24-8. PubMed ID: 11468992
[TBL] [Abstract][Full Text] [Related]
13. Antibodies and gene therapy: teaching old 'magic bullets' new tricks.
Sanz L; Blanco B; Alvarez-Vallina L
Trends Immunol; 2004 Feb; 25(2):85-91. PubMed ID: 15102367
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.
Dong H; Strome SE; Salomao DR; Tamura H; Hirano F; Flies DB; Roche PC; Lu J; Zhu G; Tamada K; Lennon VA; Celis E; Chen L
Nat Med; 2002 Aug; 8(8):793-800. PubMed ID: 12091876
[TBL] [Abstract][Full Text] [Related]
15. Comments on the Fourth International Conference on Bispecific Antibodies and Cellular Cytotoxicity, Duck Key, Florida, March 1-5, 1995.
Fanger MW; Ball ED; Drakeman DL
J Hematother; 1995 Oct; 4(5):345-9. PubMed ID: 8581367
[No Abstract] [Full Text] [Related]
16. The T-body approach: redirecting T cells with antibody specificity.
Eshhar Z
Handb Exp Pharmacol; 2008; (181):329-42. PubMed ID: 18071952
[TBL] [Abstract][Full Text] [Related]
17. Targeting of tumor cells by lymphocytes engineered to express chimeric receptor genes.
Baxevanis CN; Papamichail M
Cancer Immunol Immunother; 2004 Oct; 53(10):893-903. PubMed ID: 15168086
[TBL] [Abstract][Full Text] [Related]
18. [Monoclonal antibodies defining the differentiation cluster of the human leukocyte membrane: use of the characterization of leukocyte subsets].
Boumsell L
Ann Rech Vet; 1992; 23(3):274-80. PubMed ID: 1416735
[No Abstract] [Full Text] [Related]
19. Construction and characterization of bispecific costimulatory molecules containing a minimized CD86 (B7-2) domain and single-chain antibody fragments for tumor targeting.
Rohrbach F; Gerstmayer B; Biburger M; Wels W
Clin Cancer Res; 2000 Nov; 6(11):4314-22. PubMed ID: 11106249
[TBL] [Abstract][Full Text] [Related]
20. New aspects of natural-killer-cell surveillance and therapy of cancer.
Smyth MJ; Hayakawa Y; Takeda K; Yagita H
Nat Rev Cancer; 2002 Nov; 2(11):850-61. PubMed ID: 12415255
[No Abstract] [Full Text] [Related]
[Next] [New Search]
